Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

All NewsSeptember 9, 2025

Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent